Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Miltenyi Biotec B.V. & Co. KG. (2/27/24). "Press Release: Miltenyi Biotec Opens Its First Office in India and Plans to Invest in First of Its Kind Cell and Gene Therapy Center of Excellence". Hyderabad.

Organisations Organisation Miltenyi Biotec India Pvt. Ltd.
  Group Miltenyi Biotec (Group)
  Organisation 2 Telangana Life Sciences
  Group Telangana (govt region)
Products Product CliniMACS Prodigy® platform
  Product 2 BioAsia 2024 Hyderabad
Persons Person Stoffel, Boris (Miltenyi Biotec 201301 CEO before Memorec Stoffel)
  Person 2 Das, Annapurna (Miltenyi Biotec 202402 Managing Director India + Area Head India + Southeast Asia)

Miltenyi Biotec is launching operations in India with its first office and investing to set up Miltenyi Innovation and Technology Center as CGT Centre of Excellence (COE) in Hyderabad, India. This COE will be one of its first of its kind in India where scientists, researchers, industry experts, and clinicians can get classroom to hands-on trainings on cell and gene therapy (CGT) approaches right from proof-of-concept to pre-clinical / clinical development and commercialization. This COE also will provide Indian researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

Miltenyi Biotec is a global leader offering device, technology solutions, automated workflows, and CGT services for research and translational approaches as well as development for commercialization. This pivotal platform CliniMACS Prodigy® is uniquely positioned for end-to-end clinical development to manufacturing of CGT in an automated and functionally closed system for small-large scale manufacturing. Each year, more than 10,000 patients are treated with cell products using Miltenyi Biotec’s technologies. More than 950 investigational new drug (IND) applications as well as investigational device exemptions (IDE) with the U.S. Food and Drug Administration (FDA) are using Miltenyi Biotec’s technologies and platforms. In doing so, Miltenyi Biotec is well poised to enable local development and manufacturing in India to drive affordable and accessible CGT therapies by academia and industry for Indian as well as global patients.

The announcement was made after meeting of Mr. Revanth Reddy, Honorable Chief Minister, Telangana with Dr. Boris Stoffel, Board Member Miltenyi Biotec B.V. & Co. KG, and Managing Director Miltenyi Biotec, Dr. Toon Overstijns, Managing Director Miltenyi Biomedicine, and Ms. Annapurna Das, Managing Director India and Area Head India and Southeast Asia at BioAsia 2024. Mr. Jayesh Ranjan IAS, Principal Secretary, Industries and Commerce Department and Mr. Shakthi M. Nagappan, Chief Executive Officer, Telangana Life Sciences, were also present during the meeting.

Honorable Chief Minister Reddy said that “I am delighted to note that Miltenyi Biotec has chosen Hyderabad to set-up their first Innovation and Technology Center. It gives me immense pleasure to note that this center will be an important node to help advance novel therapies within the scientific community and promises access to healthcare options for patients both in India but also worldwide. I welcome Miltenyi to the vibrant life sciences ecosystem of Telangana. I’m also happy to note that the center will offer training in cell and gene therapy to academia and industry, which aligns with our vision of skilling university.”

Dr. Boris Stoffel, Miltenyi Biotec’s Managing Director, explains: “Miltenyi Biotec seeks to help bring new therapies to patients with high unmet medical need. Fostering knowledge exchange will be vital for CGT advancement by forging public-private partnerships like our recent MOU with BIRAC, DBT as CGT partner as well as collaborations between academic and industry partners. We have single-minded focus to drive accessibility, affordability and availability of CGT therapies by local development and manufacturing in India.”

Dr. Stoffel also highlighted that the company intends to seek opportunities to catalyze development of chimeric antigen receptor (CAR) T cell clinical development and manufacturing, with the prospect of bringing centralized and point-of-care CAR T cell therapy to hospitals across India.

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Their innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Their more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In their commitment to the scientific community, they also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 24 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. More information on

Media Contact

Miltenyi Biotec India Pvt. Ltd.
Sivakumar Natarajan
RMZ Spire, Tower 100, Office no. 07A -117
Silpa Gram Craft Village, Hitech City, Hyderabad,
Telangana -500081

Miltenyi Biotec B.V. & Co. KG
Svea Lübcke
Corporate Communications
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach

Record changed: 2024-05-08


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Miltenyi Biotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top